4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells
Meili Fu1, Fuqiang Wan2, Zhengling Li3
1Department of Infectious Disease, Linyi People's Hospital, Linyi 276000, China.
Abstract:
The aim of the present study is to investigate the potential anti-hepatocellular carcinoma (HCC) cell activity by 4SC-202, a novel class I HDAC inhibitor (HDACi). The associated signaling mechanisms were also analyzed. We showed that 4SC-202 treatment induced potent cytotoxic and proliferation-inhibitory activities against established HCC cell lines (HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. Further, adding 4SC-202 in HCC cells activated mitochondrial apoptosis pathway, which was evidenced by mitochondrial permeability transition pore (mPTP) opening, cytochrome C cytosol release and caspase-3/-9 activation. Inhibition of this apoptosis pathway, by caspase-3/-9 inhibitors, mPTP blockers, or by shRNA-mediated knockdown of cyclophilin-D (Cyp-D, a key component of mPTP), significantly attenuated 4SC-202-induced HCC cell death and apoptosis. Reversely, over-expression of Cyp-D enhanced 4SC-202's sensitivity in HCC cells. Further studies showed that 4SC-202 induced apoptosis signal-regulating kinase 1 (ASK1) activation, causing it translocation to mitochondria and physical association with Cyp-D. This mitochondrial ASK1-Cyp-D complexation appeared required for mediating 4SC-202-induced apoptosis activation. ASK1 stable knockdown by targeted-shRNAs largely inhibited 4SC-202-induced mPTP opening, cytochrome C release, and following HCC cell apoptotic death. Together, we suggest that 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to potently inhibit human HCC cells.
Insights
The novel HDAC inhibitor 4SC-202 effectively kills hepatocellular carcinoma (HCC) cells by activating the ASK1-dependent mitochondrial apoptosis pathway. This targeted approach shows promise for treating liver cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge.
- Targeting specific molecular pathways offers a promising strategy for HCC treatment.
- Histone deacetylase inhibitors (HDACi) are emerging as potential anti-cancer agents.
Purpose of the Study:
- To investigate the anti-HCC activity of 4SC-202, a novel class I HDAC inhibitor.
- To elucidate the signaling mechanisms underlying 4SC-202's effects on HCC cells.
Main Methods:
- Treatment of HCC cell lines and primary HCC cells with 4SC-202.
- Analysis of apoptosis markers, including mitochondrial permeability transition pore (mPTP) opening, cytochrome C release, and caspase activation.
- Investigating the role of cyclophilin-D (Cyp-D) and apoptosis signal-regulating kinase 1 (ASK1) in 4SC-202-induced apoptosis.
- Utilizing caspase inhibitors, mPTP blockers, and shRNA-mediated knockdown.
Main Results:
- 4SC-202 demonstrated potent cytotoxic and proliferation-inhibitory effects on various HCC cells.
- 4SC-202 activated the mitochondrial apoptosis pathway, evidenced by mPTP opening and caspase activation.
- ASK1 activation, translocation to mitochondria, and complexation with Cyp-D were crucial for 4SC-202-induced apoptosis.
- Inhibition of this pathway significantly attenuated 4SC-202's anti-cancer effects.
Conclusions:
- 4SC-202 potently inhibits human HCC cells through the activation of the ASK1-dependent mitochondrial apoptosis pathway.
- This study identifies 4SC-202 as a potential therapeutic agent for HCC.
- The findings highlight the critical role of the ASK1-Cyp-D complex in mediating HDACi-induced apoptosis in HCC.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
Inhibition of Cdk Activity
Caspases
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...


